COLANGITE PRIMARIA BILIARE 4: Comunicato congiunto AISF, EPAC e AMAF sulla raccomandazione dell’EMA di revocare l’autorizzazione alla commercializzazione di Ocaliva® in Europa Roma, 9 Luglio 2024. (FREE)

  Il 28 Giugno 2024, l’Agenzia Europea dei Medicinali (EMA) ha emesso una raccomandazione alla Commissione Europea per revocare l’autorizzazione alla commercializzazione di Ocaliva® (acido obeticolico) in Europa. In relazione a questa decisione, l’Associazione Italiana per lo Studio del Fegato (AISF) insieme alle Associazione Pazienti EPAC e AMAF desiderano inviare un messaggio ai pazienti affetti…

COLANGITE PRIMARIA BILIARE 3: IL POSITION PAPER DI AISF APPENA USCITO. DA “DIGESTIVE AND LIVER DISEASE” (FREE)

Position paper of the Italian Association for the Study of the Liver (AISF): Management and treatment of primary biliary cholangitis AISF Expert Panel 1 Introduction Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic liver disease characterized by immune-mediated inflammation and destruction of the intrahepatic, small bile ducts. In PBC patients untreated or under-treated a…

COLANGITE PRIMARIA BILIARE 2: IL TRIAL COBALT SULL’USO DELL’ACIDO OBETICOLICO. DA “AJG”

COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. Kris V Kowdley et al. OBJECTIVES: Obeticholic acid (OCA) treatment for primary biliary cholangitis (PBC) was conditionally approved in the phase 3 POISE trial. The COBALT confirmatory trial assessed whether clinical outcomes in PBC patients improve with OCA therapy. METHODS: Patients…

COLANGITE PRIMARIA BILIARE 1: UNO SPLENDIDO SEMINARIO OPEN DA “LANCET” (FREE)

Primary biliary cholangitis Prof Atsushi Tanaka et al. Summary Primary biliary cholangitis is a chronic, autoimmune, cholestatic disease that mainly affects women aged 40–70 years. Recent epidemiological studies have shown an increasing incidence worldwide despite geographical heterogeneity and a decrease in the female-to-male ratio of those the disease affects. Similar to other autoimmune diseases, primary biliary cholangitis…

CHEMIOTERAPIA ADIUVANTE DOPO RESEZIONE PER K PANCREAS POST IPMN: LINFONODI POSITIVI O NO? UN IMPORTANTE ALGORITMO DA CONSORZIO IPMN DI VERONA. DA “J Clin Oncol”

Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study Joseph R. Habib et al. for the Verona IPMN Consortium ABSTRACT PURPOSE The benefit of adjuvant therapy for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) remains unclear because of severely limited evidence. Although biologically distinct…

BACK TO BAYES ! UN GRANDE INVITO ALLA STATISTICA DI BAYES. DA “LANCET”

Bayesian statistics for clinical research Ewan C Goligher, Anna Heath, Michael O Harhay Frequentist and Bayesian statistics represent two differing paradigms for the analysis of data. Frequentism became the dominant mode of statistical thinking in medical practice during the 20th century. The advent of modern computing has made Bayesian analysis increasingly accessible, enabling growing use…